Bernard Lespérance

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen et al. · The Lancet Oncology · 2017 · 589 citations

Medicine, Oncology, Pharmacology +15

Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial

Cathy Eng, Tae Won Kim, Johanna C. Bendell et al. · The Lancet Oncology · 2019 · 562 citations · Full text

Medicine, Oncology, Pharmacology +11

HER-2/neu as a Predictive Marker in a Population of Advanced Breast Cancer Patients Randomly Treated Either with Single-agent Doxorubicin or Single-agent Docetaxel

Angelo Di Leo, Stephen Chan, Marianne Paesmans et al. · Breast Cancer Research and Treatment · 2004 · 138 citations

Medicine, Oncology, Pharmacology +11

Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2mutation carriers

Antonis C. Antoniou, Karoline Kuchenbaecker, Penny Soucy et al. · Breast Cancer Research · 2012 · 96 citations · Full text

Life Sciences, Genetics, Molecular Genetics +17

Topoisomerase-IIα expression as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel

Virginie Durbecq, Marianne Paesmans, Fátima Cardoso et al. · Molecular Cancer Therapeutics · 2004 · 93 citations

Medicine, Oncology, Pharmacology +13